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Background: Receptor-binding cancer antigen expressed on SiSo cell (RCAS1) is derived from uterine adenocarcinoma
and can induce apoptosis in lymphocytes, allowing tumor cells to escape from immune surveillance. RCAS1 is
reportedly expressed in a membranous pattern on tumor cell or soluble one in serum of patients. The aim of this study
was to investigate expression patterns of RCAS1 and the effect on apoptosis in oral squamous cell carcinoma (OSCC)
cell lines.
Methods: In four kinds of OSCC cell lines (HSC-2, HSC-3, SQUU-A, and SQUU-B), RCAS1 mRNAs and proteins were
determined by RT-PCR and immunocytochemistry. Membranous RCAS1 was determined by flow cytometry. Culture
supernatants were analyzed for detection of soluble RCAS1 by dot blotting and enzyme-linked immunosorbent assay.
Apoptotic ability of RCAS1 on the erythroid leukemia cell line K562 with the putative receptor was evaluated by flow
cytometry in co-culture with highly metastatic SQUU-B, with knocked-down RCAS1 cells or in a no-cell contact condition.
Results: RCAS1 mRNA and proteins were expressed in all of OSCC cell lines. Membranous pattern were expressed in all
cell lines, while soluble pattern was detected in all supernatants. RCAS1 mRNA, membranous and soluble RCAS1 were
significantly seen in SQUU-B more than the other 3 cell lines (P < 0.05). K562 apoptosis was induced in co-culture with
each of all cell lines, particularly with SQUU-B. Apoptosis was markedly reduced in co-culture with RCAS1 knockdown
cells, but was induced in co-culture without cell contract of SQUU-B.
Conlusions: Our study suggests that RCAS1 has an apoptotic function via membranous/soluble expression pattern in
OSCC cells. RCAS1 may thus affect tumor escape from immune surveillance in OSCC by inducing apoptosis.
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Receptor-binding cancer antigen expressed on SiSo cell
(RCAS1) is recognized by the monoclonal antibody 22-1-1,
and was initially identified in uterine adenocarcinoma
[1,2]. Its expression is reportedly correlated with clinico-
pathological parameters in 15 human cancers, such as
clinical stage, histological subtype, differentiation, tumor
size, depth of invasion, lymphovascular space involvement,
lymph node metastasis, and cytological results [3-20].
RCAS1 acts as a ligand for a putative receptor in cell lines
of several human tissue types and peripheral lymphocytes,
such as activated T, B, and NK cells. In vitro, RCAS1* Correspondence: takesea@dent.kyushu-u.ac.jp
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unless otherwise stated.inhibits growth of those activated cells and then induces
their apoptosis [21]. Similarly, RCAS1 can induce apop-
tosis of tumor infiltrating lymphocytes (TILs) in cancer
patients. This induction can lead to the escape of tumor
cells from immune surveillance, thus contributing to
tumor growth in vivo.
After proteolytic process, membranous RCAS1 is se-
creted to serum from tumor cells [22]. This process, also
called “ectodomain shedding”, affects activity of mem-
brane protein by altering its localization and mode of
action. For RCAS1, ectodomain shedding converts mem-
branous protein to soluble one, which greatly influences
its function. Soluble RCAS1 concentrations are reported
via enzyme-linked immunosorbent assay (ELISA) to be
significantly higher in patients with uterine cancer than
in healthy blood donors [23]. Moreover, change ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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with response to treatments in patients with uterine and
ovarian cancers. Compared with serum from healthy
blood donors, serum from patients with uterine and
ovarian cancers significantly inhibited growth of eryth-
roid leukemia cell line K562 that express the putative
RCAS1 receptor by inducing apoptosis [3]. Literature re-
view revealed that RCAS1 could be considered as a
biomarker since the expression was associated with im-
portant clinicopathological parameters for patient’s man-
agement and prognosis [24]. Taken together, these data
indicate that soluble RCAS1 could be a valuable bio-
marker for cancer, with the ability to improve insight
into the disease state, to facilitate diagnosis, therapeutic
strategies and disease monitoring, and to inhibit growth
of receptor-expressing cells. Thus, detection of soluble
RCAS1 in serum would be more useful than membran-
ous RCAS1 as a clinical indicator, since the apoptotic
ability of soluble RCAS1 can impact on the total ability
of tumor cell more than that of a membranous one and
blood sampling is clinically easy [22].
We previously reported that the expression of RCAS1
in oral squamous cell carcinoma (OSCC) was detected
both in cytoplasm and on membrane of tumor cell in 41
of 130 cases (31.5%) by immunohistochemistry. More-
over, the percentage of TUNEL positive TILs in patients
with RCAS1 positive OSCC was significantly higher than
in those with RCAS1 negative OSCC [25]. Furthermore,
RCAS1 expression in oral epithelial dysplasia was related
to earlier conversion to oral cancer [26]. However, no
studies on RCAS1 expression patterns in OSCC have
been reported. Moreover, the apoptotic function of
RCAS1 in OSCC is also unclear. Therefore we examined
expression kinetics of RCAS1 in OSCC cell lines, to
whether or not expression depended on characteristics
of tumor cell. We further investigated the apoptotic




Four human OSCC cell lines; HSC-2, HSC-3, SQUU-A,
and SQUU-B, the uterine adenocarcinoma cell line SiSo
as positive control and erythroid leukemia cell line K562
(which expresses the putative RCAS1 receptor) were
used in the study. HSC-2 and HSC-3 were established
from tumors of metastatic lymph nodes originating in
oral squamous cell carcinomas of different patients [27].Table 1 Primer sequence and fragment size of RCAS1
Forward primer
RCAS1 5′ATGGCCATCACCCAAGTTTCG-3′
GAPDH 5′TGACCTTGCCCACAGCCTT-3′SQUU-A and SQUU-B were established by our depart-
ment from the same patient with recurrent tongue car-
cinoma using orthotopic implantation [28]. SQUU-B
shows histologically invasive growth and has high meta-
static potential (86.7% incidence of cervical lymph node
metastasis), whereas SQUU-A demonstrates expansive
growth and has low metastatic ability. Cells were main-
tained in Dulbecco’s modified Eagle’s minimum essential
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and incubated at 37°C in a 5% CO2 atmos-
phere. Culture medium was changed on alternate days
during the experiments. This study proposal was ap-
proved by the ethical committee of Kyushu University
(No. 25–227).RNA extraction and reverse transcriptase-PCR
OSCC and SiSo cells were cultured in 10 cm dishes to
70–80% confluence. Total RNA was then extracted from
cultured cells that were harvested with a cell scraper
using Sepasol-RNA Super G (Nacalai Tesque, Kyoto,
Japan) according to the manufacturer’s instructions.
Primers were chosen through the GenBank sequence
database (NCBI, Bethesda, MD, USA). Primer pairs for
RCAS1 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) are listed in Table 1. All oligonucleotides used
as primers were synthesized by Genenet Co., Ltd (Fukuoka,
Japan). After reverse transcription with isolated mRNA,
reaction products were subjected to 28 cycles of PCR for
RCAS1 and GAPDH at 15 seconds at 94°C for denatur-
ation, 30 seconds at 60°C for annealing, and 60 seconds at
68°C for extension. PCR products were electrophoresed
on 2% agarose gels. Bands were visualized by using eth-
idium bromide. Experiments were made in triplicate. Lu-
minosity values were quantified using ImageJ software
(NIH, Bethesda, MD, USA). Mean values of triplicate
measurements were calculated.Immunocytochemistry
OSCC and SiSo cells were separately cultured on cover
glasses to 50–60% confluence. Cultured cells were fixed
in 75% methanol and then incubated with anti-mouse
IgM RCAS1 antibody (MBL, Nagoya, Japan) for 2 hours.
The cells were then incubated with secondary antibodies
conjugated with anti-mouse IgM Alexa Fluor® 488 anti-
bodies (Invitrogen, Carisbad, CA, USA) for 1 hour., and
then counterstained with Hoechst 33342 (Molecular
Probes, Eugene, Oregon, USA) for 5 minutes. FluorescentlyReverse primer Fragment size (bp)
5′-TTATGAAAGTTTCACACCAATT-3′ 642
5′-CATCACCATCTTCCAGGAGCG-3′ 443
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scope BZ-9000 (Keyence, Osaka, Japan).
Flow cytometry
OSCC and SiSo cells were separately cultured in 10-cm
dishes to 70–80% confluence. The cells were removed
from dishes with 0.5% Trypsin/EDTA (Invitrogen) and
collected by centrifugation (1200 rpm, 5 min). Cultured
cells were harvested and incubated on ice for 45 min
with RCAS1 antibody. After washing, the cells were in-
cubated on ice for 45 min with anti-mouse IgM Alexa
Fluor® 488 antibodies (Invitrogen), washed again and
subjected to flow cytometry (FACSVerse, Becton Dickinson,
San Jose, CA, USA). Isotype anti-mouse IgM antibodies
(eBioscience, San Diego, CA, USA) was used as a negative
control antibodies. Results were expressed as mean fluor-
escence intensity (MFI). Mean values of quadruplicate
measurements are shown.
Dot blotting
OSCC and SiSo cells were separately cultured in 10-cm
dishes to 70–80% confluence. The culture supernatants
were harvested for every 24-h incubation period from
day 1 to day 4. Cell-free culture media treated under the
same conditions was used as a control. To detect se-
creted RCAS1 in cell culture supernatants, chemilumin-
escent western dot blotting was performed. Briefly, each
sample was applied to a nitrocellulose filter by a blotting
apparatus (Rio-Rad, Richmond, CA, USA). Samples were
treated with 3% hydrogen peroxide for 10 min at room
temperature to remove endogenous peroxidase activity
and air-dried. Next, filters were soaked in 5% nonfat
milk in Tris-buffered saline-Tween 20 (TBS-T) contain-
ing 5% normal goat serum for 45 min at room
temperature, then incubated with RCAS1 antibody in
TBS-T containing 5% normal goat serum for 1 h at room
temperature. After washing three times with TBS-T, fil-
ters were incubated for 1 h with peroxidase conjugated
goat anti-mouse IgM–HRP antibodies (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). After washing three
times with TBS-T, filters were soaked with enhanced
chemiluminescence reagents (SuperSignal West Pico
Chemiluminescent Substrate ThermoScientific, Rockford,
IL, USA) and visualized on X-ray films.
ELISA
OSCC and SiSo cells were cultured separately in 10-cm
dishes to 70–80% confluence. Media were changed, and
the culture supernatants harvested, every after 24 h for
days 1–4. Cell-free culture media treated under the same
conditions was used as a control. In testing for soluble
RCAS1 in OSCC cell lines, RCAS1 concentrations in
culture supernatant were measured in triplicate with a
RCAS1 ELISA kit (Cusabio Biotech Co., LTD, Wuhan,Hubei Province, P.R. China), according to manufac-
turer’s instructions. Mean concentrations of quadrupli-
cate measurements are shown.
siRNA transfection in SQUU-B
Transfections were performed by using the X-treme-
GENE siRNA transfection reagent (Roche, Mannheim,
Germany), according to manufacturer’s protocol. Briefly,
SQUU-B cells were added to each well of a 6-well cul-
ture plate containing complete DMEM with 10% FBS
and incubated overnight for cell attachment. Unattached
cells were then removed by washing and fresh DMEM
medium (without antibiotics nor 10% FBS) was added.
Transfection reagent was mixed with RCAS1-siRNA
(CST, Tokyo, Japan) or negative control siRNA (Sigma-
Aldrich, lrvine, CA, USA) and incubated for 15 minutes
at room temperature. The resulting complex was then
added to each plate. After 2 days, medium was changed
to new one containing 10% FBS. The siRNA function
was confirmed by RT-PCR, flow cytometry, and ELISA.
Evaluation of apoptosis
To measure the apoptotic effect of RCAS1 as a whole in
K562, OSCC cells, SiSo and the RCAS1-knockdown
SQUU-B cells were co-cultured with K562 cells in the 6-
well cell culture plate. To measure the effect of soluble
RCAS1, SQUU-B cells and K562 cells were separately
co-cultured in a 6-well culture plate with a cell culture
insert (transparent PET membrane, 1.0-μm pore size,
BD Falcon, BD Biosciences, Franklin Lakes, NJ, USA).
Then, 1 × 105 of each effector and K562 target cell were
co-incubated in a 6 well-plate at effector/target (E/T) ra-
tios of 1:1, 5:1, 10:1, and 20:1. To discriminate K562 cells
from effector cells, K562 cells were stained by the Green
fluorescence cell linker PKH67 kit (Sigma, St.Louis, MO,
USA) before initiating the co-culture. Suspended cells
were harvested and stained with Annexin V-PE apop-
tosis detection kit (eBioscience) on days 1–4 after the
experiment. Flow cytometry was used to count apoptotic
cells after Annexin V-PE staining on days 1–4.
Statistical analysis
We assessed differences in RCAS1 expression and secre-
tion, and the Annexin-V positive ratio between different
cell groups with the Mann–Whitney U-test. P < 0.05 was
considered to be statistically significant.
Results
Expression of RCAS1 mRNA and protein in OSCC cell lines
RT-PCR results revealed that RCAS1 mRNA was de-
tected in all OSCC cell lines as in the positive control,
SiSo (Figure 1A). Luminosity analysis revealed that
highly metastatic SQUU-B significantly expressed more






































Figure 1 RCAS1 expression in OSCC cell lines (HSC-2, HSC-3, SQUU-A, SQUU-B) and SiSo (uterine adenocarcinoma cells; positive control)
using RT-PCR and immunocytochemistry. A RCAS1 mRNA was firmly detected in all OSCC cell lines. B Analysis for luminosity (Image J software)
revealed that RCAS1 mRNA of highly metastatic SQUU-B significantly scored higher than did the other 3 OSCC cells (P < 0.05; Mann–Whitney
U-test). Mean values of triplicate measurements are shown. C RCAS1 protein was diffusely expressed in both cytoplasm and on membranes in all
OSCC cell lines and SiSo, and was especially strong in SQUU-B cells (magnification × 10; bar: 100 μm).
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teins were diffusely expressed both in cytoplasm and
membrane of all OSCC cell lines as in SiSo, and was
more strongly expressed in SQUU-B (Figure 1C).
Expression of membranous RCAS1 in OSCC cell lines
Since RCAS1 is reportedly found in membranous and
soluble patterns in several cancers, we first evaluated
patterns of RCAS1 expression in OSCC cell lines. Flow
cytometric analyses revealed membranous RCAS1 to be
expressed in all OSCC cell lines (Figure 2A). Resultswere statistically compared by mean fluorescence inten-
sity (MFI). MFI of membranous RCAS1 was significantly
higher in SQUU-B (1733.8 ± 764.9) than in the other
OSCC cells: HSC-2 (317.6 ± 68.2), HSC-3 (133.3 ± 36.62),
and SQUU-A (135.0 ± 36.1) (P < 0.05; Mann–Whitney U-
test; Figure 2B).
Detection of soluble RCAS1 in supernatant of OSCC cells
Culture supernatants of OSCC cells were next examined
for soluble RCAS1. Results of dot blotting revealed that
soluble RCAS1 in culture supernatants was detected in
RCAS1
Control
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Figure 2 Expression of membranous RCAS1 in OSCC cell lines
using flow cytometry. A Membranous RCAS1 was certainly
expressed in all OSCC cell lines. B Mean fluorescence intensity (MFI)
of membranous RCAS1 was significantly higher in SQUU-B than in
the other 3 OSCC cell lines (P < 0.05; Mann–Whitney U-test). Mean
values of quadruplicate measurements are shown.



















































Figure 3 Detection of soluble RCAS1 in OSCC cell lines using
dot blotting and ELISA. A Analyses of dot blotting revealed
soluble RCAS1 in culture supernatants in all OSCC cell lines, which
increased according to culture period. B ELISA analyses revealed
significantly more soluble RCAS1 in the culture supernatant of
SQUU-B than in the other 3 OSCC cell lines at day 4 (P < 0.05;
Mann–Whitney U-test). Mean concentrations of quadruplicate
measurements are shown.
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culture period (Figure 3A). ELISA analyses found values
of soluble RCAS1 to be 49.7 ± 1.0 U/ml for HSC-2,
55.31 ± 1.2 U/ml for HSC-3, 18.1 ± 2.4 U/ml for SQUU-
A, and 64.7 ± 0.5 U/ml for SQUU-B by day 4, while were
34.6 ± 1.21 U/ml for HSC-2, 33.8 ± 1.2 U/ml for HSC-3,
6.7 ± 0.4 U/ml for SQUU-A, and 41.9 ± 0.3 U/ml for
SQUU-B by day 1. The SQUU-B supernatant signifi-
cantly carried more soluble RCAS1 than the other
OSCC cell lines by day 4 (P < 0.05; Mann–Whitney U-
test, Figure 3B).
Apoptosis of K562 cells induced by RCAS1 from OSCC
cells
RCAS1-induced apoptosis in K562 cells was analyzed
using a co-culture system with OSCC cells. Each OSCC
cell line induced apoptosis in K562 cells. The Annexin V
positive ratio of K562 increased with E/T ratios and cul-
ture periods under all co-culture conditions with eachOSCC cell line. As representative results, the ratio in-
creased in an E/T ratio-dependent fashion by co-culture
day 4; 28.4% with HSC-2, 16.6% with HSC-3, 10.8% with
SQUU-A, and 52.5% with SQUU-B at a 20:1 E/T ratio.
Apoptosis of K562 cells were more strongly induced by
co-culture with SQUU-B cells than the other 3 OSCC
cell lines (Figure 4).
Next, the same assay was conducted under different
conditions of co-culture with RCAS1 knockdown SQUU-B
cells and no-contact co-culture using a cell culture insert.
First, results of RT-PCR, flow cytometry, and ELISA con-
firmed that the RCAS1 siRNA transfection was successful
and the RCAS1 was silenced (Figure 5A–C). When K562
cells were cultured with SQUU-B as positive control, the
Annexin-V positive ratios for K562 were 1.5% at a 5:1 E/T
ratio, 2.2% at 10:1 and 3.0% at 20:1 by day 1; 5.22% at 5:1,
15.0% at 10:1, and 18.4% at 20:1 by day 2; 19.2% at 5:1,
25.9% at 10:1 and 41.7% at 20:1 by day 3; and 21.3% at 5:1,
29.7% at 10:1 and 50.5% at 20:1 by day 4. When K562 cells

































































































































































































































































































































Figure 4 Representative results for Annxin-V positive ratio of K562 cultured with OSCC cell lines. Apoptosis rates for K562 cells gradually
increased by E/T ratios and culture periods in all conditions of co-culture for each OSCC cell lines. Apoptosis of K562 was more induced in the
co-culture with SQUU-B cells than with the other 3 OSCC cell lines.
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10:1, and 0.6% at 20:1 by day 1; 0.3% at 5:1, 0.7% at 10:1,
and 1.3% at 20:1 by day 2; 3.2% at 5:1, 5.6% at 10:1, and
5.1% at 20:1 by day 3; and 3.4% at 5:1, 6.7% at 10:1 and
10.8% at 20:1 by day 4. When co-cultured with the
RCAS1-knockdown cells, 41.7% of the Annexin-V positive
cells were inhibited at a 20:1 E/T ratio by day 4. Apoptosis
of K562 cells was remarkably inhibited when co-cultured
with RCAS1 knockdown SQUU-B cells through the cul-
ture periods (Figure 6).
Even when K562 cells were cultured with SQUU-B
without cell contact, using the cell culture insert, the
K562 Annexin-V positive ratio measured by flow cytom-
etry showed apoptosis increased due to culture periods
and E/T ratios: 0.7% at 5:1, 1.0% at 10:1, and 3.8% at
20:1 by day 1; 3.9% at 5:1, 7.0% at 10:1, and 11.4% at
20:1 by day 2; 6.3% at 5:1, 9.4% at 10:1, and 18.5% at
20:1 by day 3; 11.4% at 5:1, 21.3% at 10:1, 31.5% at 20:1by day 4. Thus, apoptosis of K562 cells was induced
when cultured with only soluble RCAS1 (Figure 6).
Discussion
To our knowledge, this is the first report to find mem-
branous and soluble RCAS1 in OSCC. Expression of
RCAS1 mRNA in OSCC cells accords with that in 10
kinds of breast cancer cells [29] and 4 kinds of cholan-
giocarcinoma cells [30]. Moreover, expression of RCAS1
protein in OSCC cells accords with that in 4 kinds of
breast cancer cells [31]. These consistencies encouraged
us to further investigate its expression patterns, as im-
munocytochemical analysis individual cannot distinguish
between membranous and soluble RCAS1.
Results of flow cytometry for membranous RCAS1 in
OSCC cells are congruent with those for SiSo and
TMCC (uterine cervical cancer), MH and Kuramochi
(ovarian mucinous cancer), KF, HRA (ovarian serous










































Figure 5 RCAS1 siRNA transfection in SQUU-B. A RT-PCR analyses revealed that RCAS1 siRNA successfully reduced RCAS1 mRNA levels in
SQUU-B. B Flow cytometric analyses revealed that RCAS1 siRNA certainly down-regulated the expression of membranous RCAS1 in SQUU-B.
C ELISA analyses revealed that RCAS1 siRNA definitely down-regulated the soluble RCAS1 in SQUU-B through the culture periods. Mean
concentrations of quadruplicate measurements are shown.
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dot blotting and ELISA suggest that the soluble RCAS1
could be definitely detected in all of OSCC cells and its
concentrations were time-dependent. These results align
with findings that soluble RCAS1 in serum is signifi-
cantly increased in colon cancer patients compared with
that in healthy individuals; higher concentration of sol-
uble RCAS1 is significantly associated with advanced
Dukes’ stage and high histopathological tumor grade;
colon cancer patients with the higher concentration had
significantly shorter overall survival time; and soluble
RCAS1 is an independent prognostic factor for this ma-
lignancy [33,34].
Interestingly, the significant luminosity of RCAS1
mRNA and the significant MFI value of membranous
RCAS1 in SQUU-B suggest that RCAS1 expression is
associated with its high metastatic potential, as does its
significant increase in soluble RCAS1 levels by day 4.
Therefore, highly metastatic OSCC cells are likely to ex-
press RCAS1 as membranous or soluble proteins. In cer-
vical and ovarian cancers, the number of cells that
express mesenchymal marker vimentin is inversely re-
lated to RCAS1 expression, as remodeling of stromal tis-
sue by vimentin results in tumor invasion and metastasis[35]. Moreover, enhanced RCAS1 expression in African
Green Monkey kidney fibroblast cell lines COS-7 follow-
ing introduction of the RCAS1 gene significantly pro-
motes in vivo tumor growth via increase of vascular
endothelial growth factor [36], which implies that
RCAS1 affects tumor progression through lymph nodal
metastasis. Combined with the significant expression of
RCAS1 in SQUU-B with high metastatic potential, those
findings suggest that RCAS1 may play a pivotal role in
tumor progression by lymph nodal metastasis.
Since both results of apoptotic cell detection by staining
of Annexin V and propidium iodide were synchronized
in vitro [21] and we could confirm that apoptosis of
tumor-infiltrating lymphocytes was found by TUNNEL
staining in vivo [25], the staining of Annexin V individual
was used for the detection in this study. Results of flow cy-
tometry indicate that apoptosis of K562 cells is markedly
induced in the co-culture system with each OSCC cells,
and this incidence was dependent on RCAS1 concentra-
tion and culture periods. These results do not align with
reports that K562 apoptosis was not induced in co-culture
with MCF-7 breast cancer cells [22]. Therefore, to assess
the extent of this apoptotic ability from soluble RCAS1,





































































































































































































Figure 6 Representative results for Annxin-V positive ratio of K562 via membranous and soluble RCAS1 in SQUU-B. A Annexin-V positive
ratio of K562 cultured with SQUU-B (positive control). Apoptotic rates for K562 cells gradually increased according to E/T ratios and culture periods.
B With the RCAS1 siRNA transfection, apoptosis of K562 was remarkably inhibited. C In the co-culturing of K562 cells with SQUU-B without cell contact
(using a cell culture insert), K562 apoptosis was still induced.
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co-cultured K562 cells in medium shared with either
RCAS1-silenced or SQUU-B without direct cell contact.
By day 4 at a 20:1 E/T ratio, the Annexin-V positive ratio
was 31.5% for K562 cells cultured with SQUU-B without
direct contact, and 50.5% in K562 cells cultured in contact
with SQUU-B, which suggests that 31.5% was induced by
soluble RCAS1 versus 19.0% by membranous RCAS1.
Since membranous/soluble RCAS1 value from SQUU-B
was absolutely higher than that from positive control SiSo
and SQUU-B is specific with high metastatic potential, it
might be possible that even membranous RCAS1 had the
apoptotic ability in this study. Moreover, soluble RCAS1
apparently affects apoptotic ability of OSCC cell more
than membranous RCAS1. Though apoptotic ability of
membranous and soluble RCAS1 in K562 was merely ana-
lyzed in this study, it has been reported that the cell
growth of K562 was inhibited, after the culture for
72 hours with the serum including soluble RCAS1 of
more than 10 U/ml from patients with uterine cancer
[23]. In addition, it has been also reported that the apop-
tosis of activated T cells by IL-2 was markedly induced
after culture for 72 hours with recombinant RCAS1-glutathione S-transferase fusion proteins, while the apop-
tosis of CD3-positive (non-activated) T cells was not [21].
Combined these results with our findings, though im-
mune system of patient initially finds cancer occurred via
T cell recognition and TILs attack the cancer to prevent
from the growth and the invasion, RCAS1 could finally in-
duce apoptosis of TILs such as T cells in patients with
OSCC. We previously reported that patients with RCAS1
positive OSCCs have significantly higher percentages of
TUNEL positive TILs than do patients with RCAS1 nega-
tive OSCCs [25]. These results accord with reports that
TIL apoptosis rates in colorectal [10] and gastric carcin-
omas [13] were significantly higher in RCAS1 positive
tissues than in RCAS1 negative tissues. Therefore, RCAS1-
induced apoptosis of TILs in patients with OSCC can lead
to escape of tumor cells from immune surveillance and
contribute to tumor growth in vivo.
RCAS1 could be defined as tumor-associated antigen
in OSCC as well as in other cancers. There could be
clarified to be two patterns of RCAS1 expression in
OSCC and the apoptotic ability of soluble RCAS1 could
impact on the total ability of tumor cell more than that
of membranous one like other cancers. In addition, the
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of ovarian and uterine cancer [3,23]. Thus, detection of
soluble RCAS1 in serum of patients with OSCC might
be available as a biomarker of OSCC to facilitate diagno-
sis, therapeutic strategies and disease monitoring, as well
as improving insight into the disease state. If so, RCAS1
could be applicable for OSCC treatment as a targeted
molecule. Several strategies for RCAS1 could be consid-
ered such as modulation of RCAS1 with siRNA or inhib-
ition of RCAS1 with monoclonal antibody, in order to
suppress its expression and function. The identification
of useful biomarkers is crucial and recent advances in
biomarker discovery have raised new opportunities in
the emerging fields of personalized and predictive medi-
cine. Further clinical studies are warranted to investigate
soluble RCAS1 in serum of patients with OSCC and to
clarify the association of RCAS1 expression with clinico-
pathological parameters.
Conclusion
RCAS1 has an apoptotic function via membranous and
soluble expression in OSCC cells. Moreover, soluble
RCAS1 could extremely impact on the ability, compared
to membranous one. RCAS1 may thus affect tumor escape
from immune surveillance in OSCC by inducing apoptosis.
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